NWI Management’s AstraZeneca AZN Stock Holding History

NWI Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100,000	Closed	-$13.3M	–	58
2022 Q1	$13.3M	Buy	+100,000	New	+$12M	1.52%	18

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

NWI Management's AZN Position: Q1 2026 in Review

NWI Management held its AstraZeneca (AZN) position steady in Q1 2026 at 25,000 shares worth $4.93M. The position accounts for 0.28% of the portfolio, ranked #38.

NWI Management first reported a position in AZN in Q4 2020 and has held it in 22 quarters since. The position peaked at $19.8M in Q2 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

NWI Management held 25,000 shares of AstraZeneca worth $4.93M as of Q1 2026.
NWI Management left its AstraZeneca share count unchanged in Q1 2026.
AstraZeneca made up 0.28% of NWI Management's portfolio in Q1 2026, its #38 holding.
NWI Management first reported a position in AstraZeneca in Q4 2020 and has held it in 22 quarters since.
NWI Management's AstraZeneca position peaked at $19.8M in Q2 2022.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on NWI Management's 13F filing for Q1 2026, filed 15 May 2026.